Skip to main content

Table 1 Baseline characteristics of the studied sample

From: Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial

Clinical characteristics

Mirena group (n = 25)

Metformin group (n = 25)

Test value

p-value

Age (years)

51.61 ± 3.08

51.13 ± 2.59

221.5

0.34a

Chronic illness

 Absent

12 (48%)

8 (32%)

1.46

0.23b

 Present

13 (52%)

17 (68%)

 Hypertension

3 (12%)

8 (32%)

  

 Diabetes

9 (36%)

3 (12%)

 Asthma

2 (8%)

7 (28%)

Menopausal status

 Perimenopausal

8 (32%)

13 (52%)

2.24

0.13b

 Postmenopausal

17 (68%)

12 (48%)

Menopausal yearsc(n = 16)

 Mean ± SD

3.06 ± 1.34

2.82 ± 1.6

80

0.68a

 median (range)

3 (1 – 5)

3 (1 – 5)

Parity

3.52 ± 1.34

3.87 ± 1.1

218

0.29a

History of delivery

 Vaginal only

17 (68%)

19 (76%)

2.11

0.34a

 Caesarian only

4 (16%)

1 (4%)

 Both

4 (16%)

5 (20%)

BMI (kg/m2), mean ± SD

36.31 ± 1.33

36.98 ± 1.85

225.5

0.389a

  1. ap-values are based on the Mann Whitney U test. Statistical significance at P < 0.05
  2. bp-values are based on the chi-square test. Statistical significance at P < 0.05
  3. cFrom total postmenopausal patients